Researchers propose key elements of antimicrobial stewardship for hospitals worldwide

Antimicrobial stewardship programs (ASPs) in hospitals play a vital role in managing the threat of antibiotic resistance. To be of maximum effectiveness, essential elements of ASP programs need to be identified and standardized. Previous efforts in identifying the key components of ASPs have been confined to high-income countries. In a study to be published in the journal Clinical Microbiology and Infection, researchers identify essential elements of ASPs that could be applicable to hospitals in both high-income and low-income countries.

Researchers from Center for Disease Dynamics, Economics & Policy (CDDEP) and the Université de Lorraine in France conducted the study with the help of 15 experts from 13 countries in six continents. Through a consensus process, seven core elements that included 29 checklist items were identified. The seven core elements - leadership commitment, accountability, drug expertise, action, tracking, reporting, and education - are relevant across resource-rich and resource-limited settings. The researchers concluded that the next step should be to evaluate these core elements in a range of geographic and resource settings with broader stakeholder groups.

"An agreement of this nature will make a major contribution to slowing the spread of antibiotic resistance," said CDDEP fellow and study co-author Sumanth Gandra. "It will also facilitate the development of each nation's antimicrobial stewardship guidelines, especially in low income countries."

"With standardized ASP guidelines, analysis and evaluation of the programs will also be possible, which is an essential part of fine-tuning the practices and learning from one another," according to Celine Pulcini of the Université de Lorraine.

Pulcini C, Binda F, Lamkang AS, Trett A, Charani E, Goff DA, Harbarth S, Hinrichsen SL, Levy-Hara G, Mendelson M, Nathwani D, Gunturu R, Singh S, Srinivasan A, Thamlikitkul V, Thursky K, Vlieghe E, Wertheim H, Zeng M, Gandra S, Laxminarayan R.
Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach.
Clinical Microbiology and Infection, (2018). doi: 10.1016/j.cmi.2018.03.033.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...